Arbovax Aims to Remove the Sting from
Mosquito-Borne Diseases You can't take the bite out of the mosquito, but a small Raleigh biotechnology company
could become very big by taking the might out of that sometimes deadly bite.
The company, Arbovax, was started by British-born entrepreneur Malcolm Thomas with a
Business Development Loan for slightly more than $16,000 from the North Carolina
Biotechnology Center in 2006.
Arbovax, Inc. and
Immunobiosciences, Inc
announce a Collaborative
Agreement onDengue Vaccine
Research Arbovax, Inc (Arbovax) and
Immunobiosciences, Inc (IBI) today
announced that they will initiate research
collaboration on the development of safe
and effective vaccines for dengue, a viral
disease that is transmitted by mosquitoes.
Arbovax will use their proprietary technology
to develop host range mutations of the
dengue 2 virus and these mutants will then
be formulated with antibody into immune
complexes based on the IBI patented
process. New inventions will be jointly held
by both companies.
Welcome to Arbovax
ARBOVAX, Inc. has a unique technology that modifies arthropod-borne viruses (arboviruses) preventing them from replicating in mammalian cells. Arbovax will leverage this technology to facilitate development of a portfolio of improved vaccines against the worldwide threat of arthropod-borne diseases. read more
